Pharmaceuticals
Commercializing and developing pharmaceuticals addressing large unmet needs
Improving the lives of people suffering from mental illness and substance use disorders
Developing improved pharmaceuticals based on innovative drug delivery technologies
Providing evidence-based digital therapies to improve treatment outcomes
What we do
Digital Therapeutics
Product portfolio of scientifically proven digital therapies
Mental illness & substance use disorders
Focusing on areas of great human suffering with wider societal implications
We Care
Shedding light on lives affected by addiction and the road to recovery
Our mission for our blog platform on which we share the stories and insights from individuals coping with addiction, recovery and mental health.
Key News
APRIL 29, 2021
Q1 2021 Interim Report
APRIL 22, 2021
Invitation to presentation of the Q1 Interim Report
Our history
Strong history paving the way for the future. Learn more about our key milestones since we where founded in Uppsala, Sweden, in 1995.
Orexo Social
@OrexoABpubl
11 May 2021
At Orexo, we are passionate about improving the quality of life for our patients and society and ensuring sustainab… https://t.co/HFfqSJZjSu
@OrexoABpubl
6 May 2021
Impressed by our our partner @GAIA_COM - a world-leader in DTx - that today received fully reimbursement also for… https://t.co/jRZGdwjYxt
@OrexoABpubl
5 May 2021
Erik Penser Banks Life Science analytiker Klas Palin i en längre intervju med VD Nikolaj Sørensen. Samtalet ger en… https://t.co/V4jcoqFQp3
News Flow
Financial Snapshot
Group net revenues
621 MSEK
LTM1
Group EBITDA
-44 MSEK
LTM1
US Pharma segment EBIT
322 MSEK
LTM1
Cash position
726 MSEK
Q1 2021
1 Last Twelve Months, Q220-Q121, for more information about financial development Link